Literature DB >> 28146043

Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.

Cristina Pellegrini1, Maria Giovanna Maturo, Claudia Martorelli, Mariano Suppa, Ambra Antonini, Dimitra Kostaki, Lucilla Verna, Maria Teresa Landi, Ketty Peris, Maria Concetta Fargnoli.   

Abstract

Genetic susceptibility to cutaneous melanoma has been investigated in Italian high-risk melanoma patients from different geographical regions. CDKN2A, CDK4, and MC1R genes have been screened in most studies, MITF and POT1 were screened in only one study, and none analyzed the TERT promoter. We carried out a mutational analysis of CDKN2A, CDK4 exon 2, POT1 p.S270N, MITF exon 10, MC1R, and the TERT promoter in 106 high-risk patients with familial melanoma (FM) and sporadic multiple primary melanoma (spMPM) from Central Italy and evaluated mutations according to the clinicopathological characteristics of patients and lesions. In FM, CDKN2A mutations were detected in 8.3% of the families, including one undescribed exon 1β mutation (p.T31M), and their prevalence increased with the number of affected relatives within the family. MC1R variants were identified in 65% of the patients and the TERT rs2853669 promoter polymorphism was identified in 58% of the patients. A novel synonymous mutation detected in MITF exon 10 (c.861A>G, p.E287E), although predicted as a splice site mutation by computational tools, could not functionally be confirmed to alter splicing. For spMPM, 3% carried CDKN2A mutations, 79% carried MC1R variants, and 47% carried the TERT rs2853669 promoter polymorphism. MC1R variants were associated with fair skin type and light hair color both in FM and in spMPM, and with a reduction of age at diagnosis in FM patients. Mutations in CDK4 exon 2 and the POT1 p.S270N mutation were not detected. A low frequency of CDKN2A mutations and a high prevalence of MC1R variants characterize high-risk melanoma patients from Central Italy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28146043      PMCID: PMC7050442          DOI: 10.1097/CMR.0000000000000323

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  50 in total

1.  Influence of loss of function MC1R variants in genetic susceptibility of familial melanoma in Spain.

Authors:  Carlos de Torre; Zaida Garcia-Casado; Jorge A Martínez-Escribano; Rafael Botella-Estrada; Jose Bañuls; Vicente Oliver; Pedro Mercader; Jose M Azaña; Javier Frias; Eduardo Nagore
Journal:  Melanoma Res       Date:  2010-08       Impact factor: 3.599

2.  CDKN2A and MC1R mutations in patients with sporadic multiple primary melanoma.

Authors:  Ketty Peris; Maria Concetta Fargnoli; Alessia Pacifico; Tiziana Surrenti; Wilhem Stolz; Peter Wolf; Hans Peter Soyer; Sergio Chimenti
Journal:  J Invest Dermatol       Date:  2004-05       Impact factor: 8.551

3.  A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.

Authors:  R Kumar; J Smeds; P Berggren; O Straume; B L Rozell; L A Akslen; K Hemminki
Journal:  Int J Cancer       Date:  2001-11-20       Impact factor: 7.396

4.  High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.

Authors:  Michela Mantelli; Monica Barile; Paola Ciotti; Paola Ghiorzo; Francesca Lantieri; Lorenza Pastorino; Caterina Catricalà; Gabriella Della Torre; Ugo Folco; Paola Grammatico; Laura Padovani; Barbara Pasini; Dario Rovini; Paola Queirolo; Maria Luisa Rainero; Pier Luigi Santi; Roberto M Sertoli; Alisa M Goldstein; Giovanna Bianchi-Scarrà
Journal:  Am J Med Genet       Date:  2002-01-22

5.  CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.

Authors:  L Pastorino; L Bonelli; P Ghiorzo; P Queirolo; L Battistuzzi; E Balleari; S Nasti; S Gargiulo; S Gliori; P Savoia; S Abate Osella; M G Bernengo; G Bianchi Scarrà
Journal:  Pigment Cell Melanoma Res       Date:  2008-10-22       Impact factor: 4.693

6.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.

Authors:  Satoru Yokoyama; Susan L Woods; Glen M Boyle; Lauren G Aoude; Stuart MacGregor; Victoria Zismann; Michael Gartside; Anne E Cust; Rizwan Haq; Mark Harland; John C Taylor; David L Duffy; Kelly Holohan; Ken Dutton-Regester; Jane M Palmer; Vanessa Bonazzi; Mitchell S Stark; Judith Symmons; Matthew H Law; Christopher Schmidt; Cathy Lanagan; Linda O'Connor; Elizabeth A Holland; Helen Schmid; Judith A Maskiell; Jodie Jetann; Megan Ferguson; Mark A Jenkins; Richard F Kefford; Graham G Giles; Bruce K Armstrong; Joanne F Aitken; John L Hopper; David C Whiteman; Paul D Pharoah; Douglas F Easton; Alison M Dunning; Julia A Newton-Bishop; Grant W Montgomery; Nicholas G Martin; Graham J Mann; D Timothy Bishop; Hensin Tsao; Jeffrey M Trent; David E Fisher; Nicholas K Hayward; Kevin M Brown
Journal:  Nature       Date:  2011-11-13       Impact factor: 49.962

7.  Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma.

Authors:  Jianxin Shi; Xiaohong R Yang; Bari Ballew; Melissa Rotunno; Donato Calista; Maria Concetta Fargnoli; Paola Ghiorzo; Brigitte Bressac-de Paillerets; Eduardo Nagore; Marie Francoise Avril; Neil E Caporaso; Mary L McMaster; Michael Cullen; Zhaoming Wang; Xijun Zhang; William Bruno; Lorenza Pastorino; Paola Queirolo; Jose Banuls-Roca; Zaida Garcia-Casado; Amaury Vaysse; Hamida Mohamdi; Yasser Riazalhosseini; Mario Foglio; Fanélie Jouenne; Xing Hua; Paula L Hyland; Jinhu Yin; Haritha Vallabhaneni; Weihang Chai; Paola Minghetti; Cristina Pellegrini; Sarangan Ravichandran; Alexander Eggermont; Mark Lathrop; Ketty Peris; Giovanna Bianchi Scarra; Giorgio Landi; Sharon A Savage; Joshua N Sampson; Ji He; Meredith Yeager; Lynn R Goldin; Florence Demenais; Stephen J Chanock; Margaret A Tucker; Alisa M Goldstein; Yie Liu; Maria Teresa Landi
Journal:  Nat Genet       Date:  2014-03-30       Impact factor: 38.330

8.  POT1 loss-of-function variants predispose to familial melanoma.

Authors:  Carla Daniela Robles-Espinoza; Mark Harland; Andrew J Ramsay; Lauren G Aoude; Víctor Quesada; Zhihao Ding; Karen A Pooley; Antonia L Pritchard; Jessamy C Tiffen; Mia Petljak; Jane M Palmer; Judith Symmons; Peter Johansson; Mitchell S Stark; Michael G Gartside; Helen Snowden; Grant W Montgomery; Nicholas G Martin; Jimmy Z Liu; Jiyeon Choi; Matthew Makowski; Kevin M Brown; Alison M Dunning; Thomas M Keane; Carlos López-Otín; Nelleke A Gruis; Nicholas K Hayward; D Timothy Bishop; Julia A Newton-Bishop; David J Adams
Journal:  Nat Genet       Date:  2014-03-30       Impact factor: 38.330

9.  Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.

Authors:  Mohamed Ali Mosrati; Kerstin Willander; Ingrid Jakobsen Falk; Monica Hermanson; Martin Höglund; Dick Stockelberg; Yuan Wei; Kourosh Lotfi; Peter Söderkvist
Journal:  Oncotarget       Date:  2015-09-22

10.  Variants at the 9p21 locus and melanoma risk.

Authors:  Livia Maccioni; Panduranga Sivaramakrishna Rachakonda; Justo Lorenzo Bermejo; Dolores Planelles; Celia Requena; Kari Hemminki; Eduardo Nagore; Rajiv Kumar
Journal:  BMC Cancer       Date:  2013-07-02       Impact factor: 4.430

View more
  10 in total

1.  POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families.

Authors:  Erica Shen; Joanne Xiu; Giselle Y Lopez; Rex Bentley; Ali Jalali; Amy B Heimberger; Matthew N Bainbridge; Melissa L Bondy; Kyle M Walsh
Journal:  J Med Genet       Date:  2020-01-14       Impact factor: 6.318

2.  POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.

Authors:  M Potrony; J A Puig-Butille; M Ribera-Sola; V Iyer; C D Robles-Espinoza; P Aguilera; C Carrera; J Malvehy; C Badenas; M T Landi; D J Adams; S Puig
Journal:  Br J Dermatol       Date:  2019-02-27       Impact factor: 9.302

3.  3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.

Authors:  David Tovar-Parra; Sebastián Ramiro Gil-Quiñones; John Nova; Luz D Gutiérrez-Castañeda
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

4.  Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.

Authors:  William Bruno; Claudia Martinuzzi; Bruna Dalmasso; Virginia Andreotti; Lorenza Pastorino; Francesco Cabiddu; Marina Gualco; Francesco Spagnolo; Alberto Ballestrero; Paola Queirolo; Federica Grillo; Luca Mastracci; Paola Ghiorzo
Journal:  Oncotarget       Date:  2017-12-14

5.  Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.

Authors:  Thomas P Potjer; Sander Bollen; Anneliese J E M Grimbergen; Remco van Doorn; Nelleke A Gruis; Christi J van Asperen; Frederik J Hes; Nienke van der Stoep
Journal:  Int J Cancer       Date:  2019-01-21       Impact factor: 7.396

6.  Familial Melanoma: Diagnostic and Management Implications.

Authors:  Mariarita Rossi; Cristina Pellegrini; Ludovica Cardelli; Valeria Ciciarelli; Lucia Di Nardo; Maria Concetta Fargnoli
Journal:  Dermatol Pract Concept       Date:  2019-01-31

7.  Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup.

Authors:  W Bruno; B Dalmasso; M Barile; V Andreotti; L Elefanti; M Colombino; I Vanni; E Allavena; F Barbero; E Passoni; B Merelli; S Pellegrini; F Morgese; R Danesi; V Calò; V Bazan; A V D'Elia; C Molica; F Gensini; E Sala; V Uliana; P F Soma; M Genuardi; A Ballestrero; F Spagnolo; E Tanda; P Queirolo; M Mandalà; I Stanganelli; G Palmieri; C Menin; L Pastorino; P Ghiorzo
Journal:  ESMO Open       Date:  2022-06-28

Review 8.  Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review.

Authors:  Nikola Serman; Semir Vranic; Mislav Glibo; Ljiljana Serman; Zrinka Bukvic Mokos
Journal:  Bosn J Basic Med Sci       Date:  2022-09-16       Impact factor: 3.759

Review 9.  Telomere Maintenance Mechanisms in Cancer.

Authors:  Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre
Journal:  Genes (Basel)       Date:  2018-05-03       Impact factor: 4.096

10.  CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study.

Authors:  Jose D Tovar-Parra; Luz D Gutiérrez-Castañeda; Sebastián R Gil-Quiñones; Jhon A Nova; Leonardo Pulido
Journal:  Biomed Res Int       Date:  2020-10-10       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.